Please provide your email address to receive an email when new articles are posted on . In an observational cohort study, researchers examined Medicare beneficiaries who recently started using an AV ...

A heparin-coated endovascular prosthesis has received approval from the US Food and Drug Administration (FDA) for treatment of stenosis or thrombotic occlusions at the venous anastomosis of synthetic ...

early-dialysis-av-fistula-graft-surgery In the first few months of hemodialysis, one additional provider visit per month increased the probability of AV fistula or graft surgery by nearly 5%. When ...

April 23, 2009 — Five of 10 autologous tissue-engineered vascular grafts, implanted as arteriovenous shunts for hemodialysis access in patients with end-stage renal disease, continued to function ...

A combination of aspirin and the antiplatelet drug dipyridamole can significantly decrease the risk of patency loss in new arteriovenous (AV) hemodialysis (HD) grafts, according to a five-year study. ...

OAK BROOK, Ill. – Compared to other races, African American patients are more likely to experience premature arteriovenous (AV) graft failure in the treatment of advanced kidney failure, according to ...

Please provide your email address to receive an email when new articles are posted on . Researchers found one-fifth of surgeons diverged from recommended best practice guidelines by using an ...

Using a stent graft to keep open failing arteriovenous dialysis grafts results in better patency and fewer reinterventions than angioplasty alone. Twelve-month results of the RENOVA trial were ...

Compared to other races, African American patients are more likely to experience premature arteriovenous (AV) graft failure in the treatment of advanced kidney failure, according to a study published ...

May 20, 2009 — Treatment with dipyridamole plus aspirin improves hemodialysis graft patency, according to the results of a randomized, double-blind, placebo-controlled trial reported in the May 21 ...

Among patients with new synthetic arteriovenous hemodialysis grafts, supplementation with fish oil does not decrease the proportion of grafts with loss of native patency within 12 months compared with ...